Radiopharm Theranostics Limited Sponsored ADR (RADX) Price & Analysis

Compare

21 Followers

RADX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.08 - $50.82

Previous CloseN/A

Volume12.21K

Average Volume (3M)21.36K

Market Cap

$37.00M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Sep 25, 2025

EPS Estimate

-1.96

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.94

Shares Outstanding7,883,165

10 Day Avg. Volume27,941

30 Day Avg. Volume21,363

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$20.00

Price Target Upside324.63% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical ProgressThe Data Safety Monitoring Committee concluded that the Phase I trial of Lu-177-RAD204 can proceed to the next dose level, indicating positive clinical progress.

Financial SupportCash runway extends to June 2026, and Lantheus Holdings' investment provides financial support and potential acquisition interest.

Market ValuationThe market is perceived to be dramatically undervaluing the opportunity presented by RADX's diverse radiopharmaceutical pipeline.

Bears Say

Capital Markets EnvironmentThe analyst has adjusted the price target to reflect a challenging capital markets environment, which may impact future valuations.

Clinical ChallengesThere are concerns regarding the theoretical limitation of kidney exposure, which may limit the dose of RAD204, posing a challenge in finding a therapeutic window.

Radiopharm Theranostics Limited Sponsored ADR News

Radiopharm reports FY25 closing cash balance $29.12M

Net cash outflows from operating activities for the year totaled $36.67 million. Direct Research and Development expenditure and...

16d ago

RADX

Radiopharm receives IND approval from US FDA to initiate study of RV-01

Radiopharm (RADX) Theranostics announced that the U.S. Food and Drug Administration, FDA, has provided clearance of the Company’s...

17d ago

RADX

Radiopharm appoints Sartor to Scientific Advisory Board

Radiopharm (RADX) Theranostics announces the appointment of DrOliver Sartor, MD to the Company’s Scientific Advisory Board, SAB. Published...

23d ago

RADX

Radiopharm initiated with a Buy at Brookline

Brookline analyst Kemp Dolliver initiated coverage of Radiopharm (RADX) with a Buy rating and $18 price target The...

24d ago

RADX

Radiopharm Theranostics: Promising Pipeline and Strategic Advancements Drive Buy Rating

Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Radiopharm Theranostics Limited Sponsored ADR, retaining the...

15d ago

RADX

Radiopharm Theranostics Limited: Promising Clinical Developments and Strategic Growth Potential Drive Buy Rating

Radiopharm Theranostics Limited Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

16d ago

RADX

Radiopharm, Cyclotek signs clinical supply agreement for Tb-KLK3-mAb

Radiopharm (RADX) Theranostics announced the signing of a supply agreement with Cyclotek to radiolabel RAD 402 with Terbium-161...

2M ago

RADX

Radiopharm Theranostics Limited – American Depositary Shares trading resumes

10:51 EDT Radiopharm (RADX) Theranostics Limited – American Depositary Shares trading resumes Published first on TheFly – the...

2M ago

RADX

Radiopharm granted U.S. FDA FTD for RAD101

Radiopharm (RADX) Theranostics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD,...

2M ago

RADX

Radiopharm announces dosing of first patient in Phase 1 HEAT trial

Radiopharm (RADX) Theranostics announced the dosing of the first patient in its Phase 1 ‘HEAT’ clinical trial of...

2M ago

RADX

Radiopharm reports preclinical Lu177-B7H3-mAb data

Radiopharm (RADX) Theranostics announced that preclinical data from studies with the Lu177-B7H3-monoclonal antibody RV01 demonstrated favourable biodistribution and...

2M ago

RADX

Radiopharm pipeline ‘dramatically’ undervalued, says JonesResearch

JonesResearch analyst Justin Walsh reiterates a Buy rating on Radiopharm (RADX) and announced a $30 price target on...

3M ago

RADX

Radiopharm Theranostics Secures Lutetium-177 Supply Agreement with ITM

The latest announcement is out from Radiopharm Theranostics Limited Sponsored ADR ( ($RADX) ). On May 19, 2025,...

3M ago

RADX

Radiopharm Theranostics Engages in Key Healthcare Conferences

Radiopharm Theranostics Limited Sponsored ADR ( ($RADX) ) has provided an update. Radiopharm Theranostics announced its participation in...

5M ago

RADX

RADX FAQ

What was Radiopharm Theranostics Limited Sponsored ADR’s price range in the past 12 months?

Radiopharm Theranostics Limited Sponsored ADR lowest stock price was $3.08 and its highest was $50.82 in the past 12 months.

What is Radiopharm Theranostics Limited Sponsored ADR’s market cap?

Radiopharm Theranostics Limited Sponsored ADR’s market cap is $37.00M.

When is Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date?

Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date is Sep 25, 2025 which is in 42 days.

How were Radiopharm Theranostics Limited Sponsored ADR’s earnings last quarter?

Radiopharm Theranostics Limited Sponsored ADR released its earnings results on Feb 28, 2025. The company reported -$1.94 earnings per share for the quarter, beating the consensus estimate of -$1.969 by $0.029.

Is Radiopharm Theranostics Limited Sponsored ADR overvalued?

According to Wall Street analysts Radiopharm Theranostics Limited Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Radiopharm Theranostics Limited Sponsored ADR pay dividends?

Radiopharm Theranostics Limited Sponsored ADR does not currently pay dividends.

What is Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate?

Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate is -1.96.

How many shares outstanding does Radiopharm Theranostics Limited Sponsored ADR have?

Radiopharm Theranostics Limited Sponsored ADR has 7,883,165 shares outstanding.

What happened to Radiopharm Theranostics Limited Sponsored ADR’s price movement after its last earnings report?

Radiopharm Theranostics Limited Sponsored ADR reported an EPS of -$1.94 in its last earnings report, beating expectations of -$1.969. Following the earnings report the stock price went down -2.153%.

Which hedge fund is a major shareholder of Radiopharm Theranostics Limited Sponsored ADR?

Currently, no hedge funds are holding shares in RADX

Radiopharm Theranostics Limited Sponsored ADR Stock Smart Score

Neutral

Fundamentals

Return on Equity

-111.73%

Trailing 12-Months

Asset Growth

32.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Radiopharm Theranostics Limited Sponsored ADR

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Radiopharm Theranostics Limited Sponsored ADR (RADX) Earnings & Revenues

Historic Earnings Reports

RADX Stock 12 Month Forecast

Average Price Target

$20.00

▲(324.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","31":"$31","9.25":"$9.25","16.5":"$16.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,6.2676923076923075,8.245384615384616,10.223076923076924,12.200769230769232,14.17846153846154,16.156153846153845,18.133846153846154,20.111538461538462,22.08923076923077,24.06692307692308,26.044615384615387,28.02230769230769,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,5.498461538461538,6.706923076923077,7.915384615384616,9.123846153846154,10.332307692307692,11.540769230769232,12.74923076923077,13.957692307692309,15.166153846153847,16.374615384615385,17.583076923076923,18.79153846153846,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,4.883076923076923,5.476153846153846,6.069230769230769,6.662307692307692,7.2553846153846155,7.848461538461539,8.44153846153846,9.034615384615385,9.627692307692307,10.220769230769232,10.813846153846153,11.406923076923077,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.63,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.63,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.63,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.63,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.86,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.16,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.61,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.49,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.64,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >